CS Paper Radar

"It's still 100% on me": Designing AI Tools for the Intersection of Physicians' Care and Legal Infrastructures

Gennie Mansi, Julia Kim, Lynn Dombrowski, Mark Riedl, Naveena Karusala

cs.HC ·submitted 2026-11-11 03:43 UTC · v1

Abstract

Laws and regulations deeply shape physicians' workflows and impact how they incorporate AI-based decision support tools to care for patients. Despite calls to comply with legal standards, many AI-based decision support tools have not transitioned well to clinical settings. The medical community remains concerned about their legal liability, risks to patients, and limited clinical value of such tools. To better understand how to address these concerns in the design of AI tools for clinical decision-making, we conducted 19 interviews with physicians in the U.S. We used scenario-based design to investigate physicians' legal concerns in the context of an AI-based drug recommendation tool. Drawing on the ethics of care, we surface connections between physicians' care and the healthcare laws and regulations that deeply shape their information needs. We describe how physicians wanted to use the tool in individual and collective practices to care for themselves, their patients, their colleagues, work institution, and even the broader medical profession. We discuss how the design of AI-based decision support tools can present legal ambiguities that would prevent their caring actions and lead to non-use of the AI tool. Through our work, we contribute to responsible AI development in healthcare. Our analysis illuminates why and how certain kinds of information reduce legal ambiguity and support physicians' care when using AI-based decision support tools. We contribute an understanding of how to help physicians navigate legal liability and draw implications for grounding AI tools' designs in their care.

Comment
27 pages, 0 figures

Closest papers

Nearest neighbours by meaning across the whole index.

AI Model Design and Physician Liability

cs.AI econ.TH ·2026-08-12 ·Shujie Luan, Shubhranshu Singh, Tinglong Dai
similarity 0.69
Abstract · Forthcoming in Management Science. 66 pages, 8 figures, 5 tables; includes online appendix (pp. oa1-oa15)

Clinical algorithms can perform differently across patient groups, a concern that grows as these algorithms increasingly take the form of artificial intelligence (AI) models. In the United States, a 2024 federal rule bars healthcare providers that receive federal funds from discriminating through their use of clinical algorithms, which exposes them to liability when such use disadvantages a protected patient group. We examine how such liability considerations reshape (i) an AI firm's model design decisions that drive group-specific accuracy and (ii) a physician's decisions to use AI in healthcare delivery. The firm designs an AI model for two patient groups, and improving accuracy for the disadvantaged group is more costly. The physician (who remains the accountable decision maker) then decides whether to consult AI, weighing the reduction in clinical uncertainty against expected liability exposure when AI errors disproportionately affect the disadvantaged group. We find that this liability can induce disparate use of AI: the physician may reduce AI use overall and, over an intermediate range of liability, rely on AI less for disadvantaged patients. The effect is non-monotone. As liability increases, the physician's use of AI for disadvantaged patients first declines, then rises as the firm reallocates investment toward reducing disparity or switches to an equal-accuracy design. Mandating equal algorithmic accuracy across patient groups can then inadvertently harm both groups, because a uniform accuracy requirement distorts the firm's investment incentives and the physician's equilibrium AI-use decisions.

0.10

"It Feels Weird to Just Rely on AI": How Experienced Healthcare Professionals Work With Decision Support Systems in Clinical Practice

cs.HC ·2026-10-29 ·Simon W. S. Fischer, Hanna Schraffenberger, Miranda L. van Hooff, Casper Reijnen, Serge Thill +1 more
similarity 0.68
Abstract

Decision support systems (DSS) assist with clinical decision-making. Little is known, however, about the decision-making process with DSS in clinical practice and the extent to which clinicians consider or rely on the predictions. Studies on human-AI decision-making usually focus on laypeople, simplified decision tasks, or one-shot interactions with prototypes that are not integrated into existing workflows. To gain insights from real-world practice, we conducted an online survey (n=12) and semi-structured interviews (n=10) with clinicians from two different medical cohorts each working with a DSS. Findings show, amongst other things, that the interaction with DSS changes as experience increases, the predictions become more important in complex cases, that decisions are discussed with colleagues, and that workflow integration affects decision-making. Our findings on human, technical, contextual, and organisational factors contribute to a socio-technical perspective on DSS reliance behaviour. We conclude by discussing the implications of our findings for the design of DSS.

0.21

Reaching the last mile? How Design Decisions Shape Medical Device Qualification and Classification of Patient Support Chatbots in the EU

cs.HC ·2026-08-25 ·Milo Marsfeldt, Frantisek Kasl, Michal Koščík, Pavel Loutocky, Vaclav Stupka +2 more
published similarity 0.68
Abstract · 25 pages, 2 figures

Few AI chatbots have transitioned the 'last mile' from research prototypes to clinical practice, partly because mapping conversational design decisions to regulatory requirements is complicated. This paper presents a design-oriented regulatory analysis of a chatbot supporting stroke survivors. Using Design Space Analysis operationalised through the QOC (Questions, Options, Criteria) framework, HCI researchers and legal scholars assess how variations in three conversational functions - health Q\&A, recovery monitoring, and motivating medical adherence - influence qualification and classification under the European Medical Device Regulation (MDR), General Data Protection Regulation (GDPR), and AI Act (AIA). Our findings show that seemingly minor design decisions - such as role, actionability, and proactivity - influence regulatory obligations. The paper contributes insights into ten conversational design considerations influencing regulatory interpretation and demonstrates how QOC can support integrating legal considerations into human-centred design workflows. Finally, we suggest compliance-aware pathways to market, while reflecting on whether all chatbots should pursue the 'last mile'.

0.30

ETHOS: Towards a Modular Ethics Framework for Clinical Multi-Agent Systems

cs.MA cs.AIcs.LG ·2026-08-15 ·Rakesh Sharma, Sydney Pugh, Cameron Beeche, Pankhuri Singhal, Rachel Wu +12 more
similarity 0.66
Abstract · Preprint of an article submitted for consideration in Pacific Symposium on Biocomputing ©2027 World Scientific Publishing Company. \url{http…

The rapid adoption of large language models has enabled the development of clinical multi-agent systems (MAS) capable of integrating multimodal patient data and supporting increasingly complex clinical decision-making. However, the deployment of these systems in real-world healthcare settings raises critical ethical concerns related to safety, fairness, accountability, transparency, and patient trust. While numerous organizations, including the World Health Organization, the National Academy of Medicine, and the FUTURE-AI consortium, have proposed ethical frameworks and governance principles for healthcare AI, these efforts remain largely conceptual. To address this challenge, we present ETHOS (Ethics and Trust through Hierarchical Oversight System), a modular ethics framework designed as a governance meta-agent that can be integrated with any existing multi-agent system without requiring changes to its underlying architecture. ETHOS translates stakeholder-informed ethical requirements into executable runtime oversight through a layered governance approach consisting of deterministic checks, contextual reviews, and a final ethics critic. These components continuously evaluate intermediate reasoning steps and final outputs, enabling the system to identify ethical risks, request revisions, or suppress responses that fail predefined safety and trustworthiness criteria. We demonstrate ETHOS within a hepatology clinical decision-support MAS. Results show that ETHOS improves decision reliability by detecting incomplete, inconsistent, or out-of-scope evidence and appropriately increasing abstention when safe recommendations cannot be supported. By embedding ethical governance directly into system operation, ETHOS provides a practical and auditable mechanism for transforming high-level AI ethics principles into deployable safeguards.

0.17

HIPAA-Compliant AI Deployment Patterns in Clinical Settings: Privacy-Preserving Techniques and Governance Controls

cs.CY ·2026-08-13 ·Vinod Dhiman
similarity 0.66
Abstract

Artificial intelligence (AI) is moving from research prototypes into clinical workflows, yet the deployment of AI systems that process protected health information (PHI) remains constrained by the U.S. Health Insurance Portability and Accountability Act (HIPAA) and by the absence of shared engineering guidance for satisfying it. Existing work tends to treat privacy-preserving machine learning and regulatory governance as separate concerns, leaving practitioners without a concrete mapping from architectural decisions to compliance obligations. This paper contributes a catalog of five reusable deployment patterns for clinical AI that jointly address the HIPAA Privacy and Security Rules: a de-identified analytics zone, cross-entity federated learning, confidential inference within trusted execution environments, a PHI-minimizing retrieval-augmented clinical assistant, and a synthetic data sandbox for development. Each pattern is specified in terms of context, governing forces, structure, and residual risk, and is mapped to the administrative, physical, and technical safeguards of the HIPAA Security Rule as well as to the NIST AI Risk Management Framework and ISO/IEC~42001. We further present a threat model for clinical AI and a decision procedure for selecting patterns based on data sensitivity, trust boundaries, and latency requirements. The goal is to give security engineers, compliance owners, and clinical informaticists a common vocabulary that turns abstract regulatory duties into verifiable architectural controls.

0.04

AI Can Be Easily Persuaded in Clinical Decision Making

cs.CL cs.AI ·2026-08-29 ·Jiayuan Zhu, Jiazhen Pan, Fenglin Liu, Minhao Hu, Junde Wu
similarity 0.65
Abstract

As AI becomes increasingly integrated into clinical practice, it is playing a growing role in medical decision making. Medicine, however, is a high stakes and evidence based field, where decisions can directly affect patients' lives. It is therefore important to understand whether AI can maintain objective judgment when others try to persuade it. In this paper, we study how easily AI can be persuaded through controlled experiments. We find that professional authority, national background, institutional affiliation, claimed past performance, multiple physicians, supported clinician views, and repeated pressure can all affect AI decisions. Surprisingly, the same persuasive input changes about 10% more cases when it comes from a senior clinician than from a medical student. Simply claiming a better performance history consistently makes the physician more persuasive. More strikingly, a plausible clinician view can persuade AI away from a correct decision even when it is fabricated to support an incorrect answer. This indicates that AI can be strongly influenced by convincing support without reliably determining whether this view from the clinician is correct. Together, these findings suggest that AI can be easily persuaded by what people say, who says it, and how the opinion is presented. Therefore, it is essential for AI to maintain sound judgment under persuasion, enabling its safe and reliable use in high stakes medical decision making.

0.33

RAG-Enhanced LLMs for Interactive Explainability in Clinical Decision Support Systems

cs.AI cs.HCcs.LG ·2026-11-06 ·Lorenzo Mannocci, Francesca Naretto, Lucia Passaro, Anna Monreale
published similarity 0.65
Abstract · Published in HC_AIxIA_HYDRA 2025, Communications in Computer and Information Science, vol. 2830, pp. 50-63, Springer, 2026. Please cite the …

Artificial Intelligence (AI) is increasingly embedded in high-risks decision-making systems across domains such as healthcare, finance, and the judicial system. As reliance on predictive models grows, so does the demand for Explainable AI (XAI) to ensure transparency, trust, and interpretability. However, existing XAI approaches often fail to present explanations in a format accessible to domain experts, limiting their practical utility. Large Language Models (LLMs) have recently emerged as a bridge between complex models and end-users, offering natural language explanations. Yet, their use introduces new risks, including hallucinated outputs and lack of source traceability. To address these challenges, we propose a Clinical Decision Support System (CDSS) that not only combines standard predictive models with XAI techniques but also incorporates a Retrieval-Augmented Generation module as an interactive enhancer. This module grounds explanations in verified medical knowledge, reformulates technical outputs into a human-like format, and enables users-such as clinicians-to actively query the system. By fostering an interactive, human-in-the-loop environment, our approach empowers domain experts to explore model decisions, contextualize explanations, and build trust in AI-assisted diagnostics. The study concludes with preliminary experiments validating the proposed methodology.

0.20

VITAL: A Framework for Validating Agentic AI in Pharmaceutical Drug Development and Clinical Trial Operations

cs.AI ·2026-11-17 ·Sandeep Burugupalli, Pedro Matos-Filipe, Andrea Hita Ardiaca, Adam Taylor, Alex Grigorenko +8 more
similarity 0.64
Abstract

Current assurance approaches do not establish whether evidence is sufficient to validate, monitor and govern agentic artificial intelligence (AI) within a pharmaceutical context of use. Plausible outputs may conceal failures in retrieval, reasoning, orchestration or human-control points, where reference standards are unavailable. We developed and operationalised VITAL (Validation by Intended use, Traceability, Autonomy and Lifecycle evidence), a validation framework for agents in clinical development, through landscape analysis, regulatory and standards mapping, expert interviews and multi-stakeholder refinement. VITAL integrates context of use, controls, behavioural validation and lifecycle evidence within a risk-adjusted framework. We applied VITAL across epidemiology and treatment-landscape analysis, site selection, enrolment rescue and trial-design trade-off support to translate autonomy, reversibility, transparency and patient impact into proportionate validation activities, evidence requirements and auditable reconstruction of system behaviour. VITAL may inform evidence requirements and lifecycle accountability for higher-risk pharmaceutical uses; evaluation should assess reproducibility across assessors, organisations and system configurations.

0.25